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Background
Pulmonary hypertension is a disabling disease associated
with high mortality [1,2]. Riociguat (under review for
the treatment of pulmonary hypertension) stimulates
soluble guanylate cyclase, which plays an important role
in the regulation of cardiovascular tone and remodelling
[3-9]. We investigated the potential effects of age and
gender on the pharmacokinetics of riociguat and its pri-
mary metabolite M1 (BAY 60-4552). Safety and toler-
ability of riociguat were also assessed.
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Figure 1 Mean riociguat plasma concentrations in groups of differing age and gender following administration of a single oral dose of riociguat
2.5 mg.
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Methods
This placebo-controlled, double-blind, single-centre
study followed good clinical practice guidelines. Healthy
volunteers were randomized into four groups according
to age (young, 18–45 years; elderly, 64.5–80 years) and
gender: young male (YM), elderly male (EM), young
female (YF), elderly female (EF). All participants received
a single oral tablet of riociguat 2.5 mg or placebo. Dense
sampling was performed for pharmacokinetics.
Results
Forty-seven participants provided data for pharmacoki-
netic and safety analyses. Nine participants in each group
received riociguat; three participants in each of the YM,
EM and EF groups and two participants in the YF group
received placebo.
Age: the mean maximum concentration of riociguat in
plasma (Cmax) did not vary markedly between age
groups (Figure 1). However, mean renal clearance was
decreased in the elderly, and exposure (area under the
plasma concentration–time curve [AUC]) to riociguat
was approximately 40% higher in the elderly than in the
young (p > 0.05) (Tables 1 & 2). When normalized for
body weight, the riociguat exposure (AUCnorm) ratio
was reduced; AUCnorm was approximately 30% higher in
the elderly than in the young (Tables 1 & 2).
Gender: although riociguat mean Cmax normalized for
body weight (Cmax,norm) was significantly greater in
Table 1 Selected pharmacokinetic parameters of riociguat and metabolite M1 (BAY 60-4552) by age and gender
following a single oral dose of riociguat 2.5 mg
Parameter Young female (n = 9) Elderly female (n = 9) Young male (n = 9) Elderly male (n = 9)
Riociguat
AUC, μg·h/L 803 (55) 1145 (36) 750 (58) 1036 (48)
Cmax, μg/L 113 (22) 125 (35) 80.4 (25) 96.7 (32)
AUCnorm, g·h/L 24.8 (57) 32.6 (45) 26.5 (55) 32.8 (50)
Cmax,norm, g/L 3.48 (20) 3.56 (36) 2.84 (23) 3.06 (22)
t½, h 8.97 (51) 11.8 (31) 8.10 (39) 12.2 (62)
CLR, L/h
a 0.320 (28) 0.223 (33) 0.389 (37) 0.287 (28)
M1
AUC, μg·h/L 640 (26) 651 (38) 476 (20) 687 (44)
Cmax, μg/L 28.1 (53) 22.4 (52) 14.9 (44) 18.8 (71)
AUCnorm, g·h/L 20.5 (26) 19.2 (30) 17.4 (28) 22.5 (35)
Cmax,norm, g/L 0.899 (51) 0.661 (42) 0.544 (51) 0.615 (65)
t½, h 16.0 (34) 16.7 (21) 14.9 (28) 21.3 (33)
CLR, L/h
a 0.824 (32) 0.487 (36) 0.718 (39) 0.573 (44)
aArithmetic mean (percentage coefficient of variation). All other parameters are expressed as geometric means (percentage coefficient of variation).
AUC, area under the plasma concentration–time curve from time 0 to infinity; AUCnorm, AUC divided by dose per kilogram of body weight; Cmax, maximum
concentration in plasma; Cmax,norm, Cmax divided by dose per kilogram of body weight; t½, terminal elimination half-life; CLR, renal clearance.
Table 2 Comparison of selected riociguat and M1 pharmacokinetic parameters between different participant groups
(ratios and 90% confidence limits)
Parameter Elderly vs young (n = 18 per group) Female vs male (n = 18 per group)
Riociguat
AUC 1.40 (1.06–1.86) 1.09 (0.82–1.44)
Cmax 1.16 (0.98–1.36) 1.35 (1.14–1.59)*
AUCnorm 1.28 (0.95–1.71) 0.97 (0.72–1.30)
Cmax,norm 1.05 (0.91–1.22) 1.20 (1.03–1.38)*
t½ 1.41 (1.08–1.84)* 1.04 (0.79–1.35)
M1
AUC 1.21 (1.00–1.46) 1.13 (0.94–1.36)
Cmax 1.00 (0.73–1.38) 1.50 (1.09–2.05)*
AUCnorm 1.10 (0.93–1.30) 1.00 (0.85–1.19)
Cmax,norm 0.91 (0.68–1.23) 1.33 (0.99–1.79)
t½ 1.22 (1.04–1.44)* 0.92 (0.78–1.08)
*p < 0.05 for ratio = 1.
AUC, area under the plasma concentration–time curve from time 0 to infinity; AUCnorm, AUC divided by dose per kilogram of body weight; Cmax, maximum
concentration in plasma; Cmax,norm, Cmax divided by dose per kilogram of body weight; t½, terminal elimination half-life.
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women than in men, no difference in exposure was
observed between genders (Tables 1 & 2).
Across age groups, pharmacokinetics of M1 followed
similar trends to those of riociguat, although differences
were less pronounced (Tables 1 & 2). Compared with the
combined placebo subgroups, the combined riociguat
subgroups demonstrated an expected reduction in mean
blood pressure and corresponding elevation of mean
heart rate, waning approximately 16 hours post-dose.
Three participants in the riociguat subgroups reported
drug-related adverse events, one of which (hypotension)
was classified as severe. All adverse events had resolved
by completion of the study.
Conclusion
Age and gender had modest effects on riociguat and M1
pharmacokinetics, and the safety profile of riociguat was
similar across all groups. Thus, no dose adjustment for age
or gender is merited.
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